Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $43
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $43
Wells Fargo analyst Derek Archila maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and adjusts the target price from $47 to $43.According to TipRanks data, the analyst has a success
Evaluating Market Dynamics and Physician Preferences: Hold Rating on Apellis Pharmaceuticals Amid Syfovre and Izervay Competition
Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $92
Baird analyst Colleen M. Kusy maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and adjusts the target price from $96 to $92.According to TipRanks data, the analyst has a success rate
Express News | Apellis Pharmaceuticals Inc : Baird Cuts Target Price to $92 From $96
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $61
BofA Securities analyst Tazeen Ahmad maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and maintains the target price at $61.According to TipRanks data, the analyst has a success rate